Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02339454
Previous Study | Return to List | Next Study

Efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy in Patients With Stable Angina Pectoris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02339454
Recruitment Status : Completed
First Posted : January 15, 2015
Last Update Posted : April 10, 2018
Sponsor:
Collaborators:
Vilnius University
Medispec
Information provided by (Responsible Party):
Evgeny Shkolnik, MD, Moscow State University of Medicine and Dentistry

Brief Summary:

Low intensity shockwaves have been proven in animal and pilot clinical studies to induce local growth of new blood vessels. Small single-center clinical trials with shockwave therapy showed promising results in reducing angina symptoms, improving perfusion and contractility in patients with refractory angina and stress-induced ischemia on imaging test.

The hypothesis of this study is that shockwave therapy could improve angina symptoms and exercise tolerance in broader population of patients with stable angina regardless of imaging test results Study aims to demonstrate anti-anginal efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy (ESMR), on top of stable optimal medical treatment in patients with stable angina.


Condition or disease Intervention/treatment Phase
Stable Angina Pectoris Device: Active treatment group Device: Placebo group Phase 3

Detailed Description:

Low intensity shockwaves (0.09 millijoule/mm2) are delivered to myocardial tissue. Shockwaves are created by a special generator and are focused using a shockwave applicator device. The treatment is guided by standard echocardiography equipment. The shockwaves are delivered in synchronization with Patient R-wave (ECG) to avoid arrhythmias. The treatment is painless.

At first, the patient undergoes modified Bruce treadmill test, to assess exercise induced ischemia.

Exercise induced ECG ischemia is defined as the new development of horizontal or down - sloping ST segment depression (≥1 mm at 60 ms after J point) versus baseline tracing.

Study treatment consists of 9 sessions, with 3 sessions per week 1, 5 and 9. 100 shocks are delivered per spot, 1200 shocks per session.

During 1st treatment week ESMR will be delivered 3 times (every other day) to basal segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).

During 2nd treatment week ESMR will be delivered 3 times (every other day) to middle segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).

During 3rd treatment week ESMR will be delivered 3 times (every other day) to apical segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).

The spots are localized by the ultra-sound device and the shockwaves are focused to this area. Several treatments are required for optimal results.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy in Patients With Stable Angina Pectoris - A Randomized, Double Blind, Placebo Controlled, Multicenter Study
Study Start Date : May 2012
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Angina

Arm Intervention/treatment
Active Comparator: Active treatment group

Patients in this group receive actual shockwave therapy. Study treatment consists of 9 sessions, with 3 sessions per week 1, 5 and 9. 100 shocks are delivered per spot, 1200 shocks per session.

During 1st treatment week ESMR will be delivered 3 times (every other day) to basal segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).

During 2nd treatment week ESMR will be delivered 3 times (every other day) to middle segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).

During 3rd treatment week ESMR will be delivered 3 times (every other day) to apical segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).

Device: Active treatment group
Energy Density - 0.09 mJ/mm2 Device: Active Applicator
Other Names:
  • Cardiospec
  • Extracorporeal Shockwave Myocardial Revascularization (ESMR)
  • Extracorporeal Cardiac Shock wave therapy (CSWT)

Placebo Comparator: Placebo group
This group of patients undergoes the same procedure as the treatment group; however shockwaves are not delivered to the heart.
Device: Placebo group
Placebo Applicator




Primary Outcome Measures :
  1. Change in Total Exercise duration [ Time Frame: 6 months ]

    To evaluate if ESMR able to improve total exercise duration in modified Bruce treadmill test.

    Patients will be assessed at baseline visit (screening) and 6 months after the first treatment.



Secondary Outcome Measures :
  1. Time to 1 mm ST-segment depression in modified Bruce treadmill test [ Time Frame: 6 months ]
  2. Time to angina in modified Bruce treadmill test [ Time Frame: 6 months ]
  3. Number of angina attacks per week [ Time Frame: 6 months ]
  4. Number of sublingual nitroglycerin consumption per week [ Time Frame: 6 months ]
  5. CCS angina functional class [ Time Frame: 6 months ]
  6. Seattle angina questionnaire score [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients (females of childbearing potential must be using adequate contraceptive precautions such as implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence or vasectomized partner).
  • Patients aged ≥ 18 years.
  • Patients with coronary artery disease confirmed by angiography, prior MI, prior revascularization (PCI, CABG) and with exercise angina not controlled by the optimal medical therapy.
  • Patient should be on a stable dosage of medication used to treat angina for at least 4 weeks prior to enrollment.
  • ST-segment depression ≥ 1mm during exercise ECG.
  • Able and willing to sign informed consent and to comply with study procedures.
  • Written informed consent prior to enrolment into the study.

Exclusion Criteria:

  • Angina at rest.
  • ECG abnormalities at rest (left bundle-branch block, resting ST-segment depression ≥ 1mm, digoxin therapy, WPW-syndrome).
  • Planned coronary intervention or CABG within 6 months.
  • Heart failure (class III or IV NYHA).
  • Moderate-severe hypertension (SBP>160 mmHg and/or DBP>100 mmHg).
  • Hypotension (SBP<100 mmHg).
  • Acute coronary syndrome or coronary revascularization procedure within the prior 3 months before enrolment.
  • Females who are pregnant or nursing.
  • Any clinically relevant hematological or biochemical abnormality on routine screening, according to Investigator's judgment.
  • Severe concurrent pathology, including terminal illness (cancer, AIDS, etc.).
  • Renal impairment defined as Creatinine >150 mcmol/l.
  • Mild, moderate or severe hepatic impairment or hepatic insufficiency defined as: SGOT or SGPT > 3 times greater than normal upper limit or total serum bilirubin > 1.5 times greater than normal upper limit
  • Existing contraindications for exercise testing (e.g. acute myocarditis or pericarditis, DVT, severe aortic stenosis)
  • Dementia, psychosis, alcoholism (>350 g ethanol/week) or chronic abuse of medicines, drugs or psychoactive substances.
  • Conditions which in the Investigator's opinion may interfere with the study's execution or due to which the patient should not participate for safety reasons.
  • Risk of low patient cooperation.
  • Inability or unwillingness to issue the informed consent.
  • Patient is simultaneously participating in another device or drug study, or has participated in any clinical trial involving an experimental device or drug, including other drugs or devices enhancing cardiac neovascularization, or any cardiac shock wave therapy machine of a competitor company within 3 months of entry into the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02339454


Locations
Layout table for location information
Lithuania
Vilnius University Hospital, Santariskiu klinkos
Vilnius, Lithuania
Russian Federation
Moscow state university of medicine&dentistry
Moscow, Russian Federation, 127473
Sponsors and Collaborators
Evgeny Shkolnik, MD
Vilnius University
Medispec
Investigators
Layout table for investigator information
Principal Investigator: Jelena Celutkiene, MD, PhD Vilnius University Hospital, Santariskiu klinikos
Principal Investigator: Evgeny Shkolnik, MD, PhD Moscow State University of Medicine&Dentistry

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Evgeny Shkolnik, MD, Professor, department of functional methods in internal medicine, Moscow State University of Medicine and Dentistry
ClinicalTrials.gov Identifier: NCT02339454     History of Changes
Other Study ID Numbers: ESMR-RCT-UP
First Posted: January 15, 2015    Key Record Dates
Last Update Posted: April 10, 2018
Last Verified: April 2018

Keywords provided by Evgeny Shkolnik, MD, Moscow State University of Medicine and Dentistry:
Cardiac Shock wave therapy
stable angina
exercise tolerance

Additional relevant MeSH terms:
Layout table for MeSH terms
Angina Pectoris
Angina, Stable
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Chest Pain
Pain
Neurologic Manifestations
Signs and Symptoms